Dr James Good

Dr James Good is a distinguished clinical oncologist specialising in a comprehensive array of oncology treatments and technologies. His expertise encompasses clinical oncology, radiotherapy, chemotherapy, and advanced techniques such as stereotactic ablative radiotherapy (SABR), targeted therapy, and immunotherapy.

With a robust clinical focus on a variety of gastrointestinal cancers including pancreatic, bowel, colorectal, colon, liver, bile duct (cholangiocarcinoma), and gallbladder cancers, as well as metastatic diseases, Dr Good excels in implementing innovative treatment modalities like Cyberknife therapy, genetic testing, and image-guided radiotherapy (IGRT). He is also proficient in intensity-modulated radiotherapy (IMRT) and volume-modulated arc therapy (VMAT).

Active in research and clinical trials, Dr Good's contributions are underpinned by his memberships in esteemed organizations such as the Royal College of Physicians, the Radiosurgery Society, the European Society of Medical Oncology, the NCRI Clinical and Translational Radiotherapy Group (CT-Rad), and the UK SABR Consortium. His commitment to advancing cancer care is reflected in his extensive experience and ongoing engagement with cutting-edge developments in cancer genomics and treatment for oligometastatic and spinal metastatic disease.